[1]王妍妍,赵永新,王建强,等.乳腺肿块患者血清和肿块组织中B细胞淋巴瘤因子3蛋白的表达及临床意义[J].新乡医学院学报,2021,38(7):649-652.[doi:10.7683/xxyxyxb.2021.07.010]
　WANG Yanyan,ZHAO Yongxin,WANG Jianqiang,et al.Clinical significance and expression of B-cell lymphoma factor 3 protein in serum and mass tissue of breast mass patients[J].Journal of Xinxiang Medical University,2021,38(7):649-652.[doi:10.7683/xxyxyxb.2021.07.010]
点击复制

乳腺肿块患者血清和肿块组织中B细胞淋巴瘤因子3蛋白的表达及临床意义
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年7
页码:
649-652
栏目:
临床研究
出版日期:
2021-07-05

文章信息/Info

Title:
Clinical significance and expression of B-cell lymphoma factor 3 protein in serum and mass tissue of breast mass patients
作者:
王妍妍1; 赵永新1; 王建强2; 康丽霞1; 王　辉3
（1.新乡医学院第三附属医院检验科，河南　新乡　453003；2.新乡医学院第三附属医院病理科，河南　新乡　453003；3.新乡医学院医学检验学院，河南　新乡　453003）
Author(s):
WANG Yanyan1; ZHAO Yongxin1; WANG Jianqiang2; KANG Lixia1; WANG Hui3
（1.Department of Clinical Laboratory,the Third Affiliated Hospital of Xinxiang Medical University,Xinxiang 453003,Henan Province,China;2.Department of Pathology,the Third Affiliated Hospital of Xinxiang Medical University,Xinxiang 453003,Henan Province,China；3.School of Laboratory Medicine,Xinxiang Medical University,Xinxiang 453003,Henan Province,China)
关键词:
乳腺肿块; 乳腺癌; B细胞淋巴瘤因子3
Keywords:
breast mass; breast cancer; B-cell lymphoma factor 3
分类号:
R737.9
DOI:
10.7683/xxyxyxb.2021.07.010
文献标志码:
A
摘要:
目的　探讨乳腺肿块患者血清和肿块组织中B细胞淋巴瘤因子3（Bcl-3）蛋白的表达及临床意义。方法　选择2017年12月至2019年3月新乡医学院第三附属医院收治的56例乳腺肿块患者为研究对象，患者术前均未接受化学治疗、放射治疗，所有乳腺肿块组织行病理学检查，根据病理学检查结果将患者分为非肿瘤组（包括乳腺炎、乳腺导管扩张症、乳腺增生症、脂膜炎、乳腺腺病）12例、良性肿瘤组（包括乳腺腺病伴导管内乳头状瘤、纤维腺瘤、纤维脂肪瘤、乳腺腺病伴纤维腺瘤、乳腺导管内乳头状瘤）24例、恶性肿瘤组（包括乳腺浸润性小叶癌、乳腺浸润性导管癌、非特殊型浸润性癌）20例；采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶法检测肿块组织中Bcl-3蛋白的表达，酶联免疫吸附试验检测患者血清中Bcl-3蛋白水平。结果　非肿瘤组、良性肿瘤组、恶性肿瘤组患者肿块组织中Bcl-3蛋白阳性表达率分别为16.67%（2/12）、54.17%（13/24）和85.00%（17/20）；恶性肿瘤组患者肿块组织中Bcl-3蛋白阳性表达率显著高于良性肿瘤组和非肿瘤组（χ2=4.781、14.521，P<0.05)，良性肿瘤组患者肿块组织中Bcl-3蛋白阳性表达率显著高于非肿瘤组（χ2=4.629，P<0.05)。非肿瘤组、良性肿瘤组、恶性肿瘤组患者血清中Bcl-3蛋白水平分别为（48.10±23.03）、（34.75±17.93）、（22.50±18.29）μg·L-1；恶性肿瘤组患者血清中Bcl-3蛋白水平显著低于良性肿瘤组和非肿瘤组（t=2.186、3.367，P<0.05），良性肿瘤组患者血清中Bcl-3蛋白水平显著低于非肿瘤组（t= 1.865，P<0.05）。结论　乳腺癌组织中Bcl-3蛋白表达上调，乳腺癌患者血清中Bcl-3蛋白水平降低，检测Bcl-3蛋白表达可能为乳腺癌的诊断提供参考。
Abstract:
Objective　To investigate the expression of B-cell lymphoma factor 3 (Bcl-3) protein in serum and breast mass tissues and its clinical significance.Methods　A total of 56 patients with breast mass admitted to the Third Affiliated Hospital of Xinxiang Medical University from December 2018 to March 2019 were selected as the research subjects.None of the patients received chemotherapy or radiotherapy before surgery.All breast mass tissues of the patients were examined by pathology.According to the pathology examination results,the patients were divided into the the tumor group (including mastitis,mammary duct ectasia,breast hyperplasia,panniculitis,breast adenosis；n=12),benign tumor group (including breast adenosis with intraductal papilloma,fibroadenoma,fibrolipoma,breast adenosis with fibroadenoma,breast intraductal papilloma；n=24) and malignant tumor group (including invasive lobular carcinoma of the breast,invasive ductal carcinoma of breast,nonspecific invasive carcinoma).The expression of Bcl-3 protein in breast mass tissues was detected by immunohistochemical Streptomyces antibiotin protein-peroxidase assay,and the serum Bcl-3 protein level of patients was detected by enzyme linked immunosorbent assay.Results　The positive expression rate of Bcl-3 protein in breast mass tissues of patients in the non-tumor group,benign tumor group and malignant tumor group was 16.67% (2/12),54.17% (13/24) and 85.00% (17/20),respectively.The positive expression rate of Bcl-3 protein in breast mass tissues of patients in the malignant tumor group was significantly higher than that in the non-tumor group and benign tumor group (χ2=4.781,14.521;P<0.05),the positive expression rate of Bcl-3 protein in breast mass tissues of patients in the benign tumor group was significantly higher than that in the non-tumor group (χ2=4.629,P<0.05).The serum Bcl-3 protein level of patients in the non-tumor group,benign tumor group and malignant tumor group was (48.10±23.03),(34.75±17.93),(22.50±18.29) μg·L-1,respectively.The serum Bcl-3 protein level of patients in the malignant tumor group was significantly lower than that in the benign tumor group and non-tumor group (t=2.186,3.367;P<0.05).The serum Bcl-3 protein level of patients in the benign tumor group was significantly lower than that in the non-tumor group (t=1.865,P<0.05).Conclusion　The expression of Bcl-3 protein in breast cancer tissues is up-regulated,and the serum level of Bcl-3 protein of breast cancer patients decreased.Detection of Bcl-3 protein expression may provide reference for the diagnosis of breast cancer.

参考文献/References:

［1］　杨敏，张娇燕，段丹，等.乳腺癌照顾者研究的文献计量学及可视化分析［J］.实用肿瘤学杂志，2021，35（2）：110-116.
［2］　王合兵，肖坚，陈文新，等.外周血CK-19、Vimentin mRNA在早期诊断乳腺癌复发、转移中的应用研究［J］.中国医学工程，2021，29（3）：35-38.
［3］　OHNO H,TAKIMOTO G,MCKEITHAN T W.The candidate proto-oncogene Bcl-3 is related to genes implicated in cell lineage determination and cell cycle control［J］.Cell,1990,60(6):991-997.
［4］　ZHAO H,WANG W,ZHAO Q,et al.BCL3 exerts an oncogenic function by regulating STAT3 in human cervical cancer［J］.Onco Targets Ther,2016,2016，9:6619-6629.
［5］　WU J,LI L,JIANG G,et al.B-cell CLL/lymphoma 3 promotes glioma cell proliferation and inhibits apoptosis through the oncogenic STAT3 pathway［J］.Int J Oncol,2016,49(6):2471-2479.
［6］　TU K,LIU Z,YAO B,et al.BCL-3 promotes the tumor growth of hepatocellular carcinoma by regulating cell proliferation and the cell cycle through cyclin D［J］.Oncol Rep,2016,35(4):2382-2390.
［7］　CHOI H J,LEE J M,KIM H,et al.Bcl3-dependent stabilization of CtBPI is crucial for the inhibition of apoptos is and tumor progre-ssion in breast cancer［J］.Biochem Biophys Res Commun,2010,400(3):396-402.
［8］　袁建良，胡永伟，丁厚中，等.Bcl-3在人乳腺癌组织中的表达及对乳腺癌MDA-MB-231细胞增殖与凋亡的影响［J］.江苏大学学报，2016，26（5）：1671-7783.
［9］　刘海娟，丁艳妮，杜绒，等.加速康复外科理念对乳腺癌改良根治术患者术后恢复的影响［J］.中国肿瘤临床与康复，2021，28（5）：623-626.
［10］　朱文超，梁敏，王金平，等.新辅助化疗对乳腺癌患者围手术期炎性因子及术后早期痛觉敏感性的影响［J］.国际麻醉学与复苏杂志，2019,40（2）：130-134.
［11］　艾小红.乳腺癌改良根治术后患者开展循证护理对其并发症及负面情绪的影响［J］.山西医药杂志，2019，48（16）：2067-2069.
［12］　黎立喜，马飞.乳腺癌筛查和早期诊断的血液生物学标志物［J］.国际肿瘤学杂志，2021，48（2）：109-112.
［13］　GARCIA-MURILLAS I,SCHIAVON G,WEIGELT B,et al.Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer［J］.Sci Transl Med,2015,7(302):302-313.
［14］　SCHWARZENBACH H,HOON D S,PANTEL K.Cell-free nucleic acids as biomarkers in cancer patients［J］.Nat Rev Cancer,2011,11(6):426-437.
［15］　CHEN R,WANG L,LIU S,et al.Bcl-3 is a novel biomarker of renal fibrosis in chronic kidney disease［J］.Oncotarget,2017,8(57):97206-97216.

相似文献/References:

[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 ． 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]郭小刚.乳腺肿块204例病理切片和活检分析[J].新乡医学院学报,2002,19(05):412.
[4]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[6]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[7]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[8]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[9]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[10]王　乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.

更新日期/Last Update: 2021-07-05